Pasithea Therapeutics Corp. [NASDAQ: KTTA] stock went on an upward path that rose over 153.39% on Tuesday, amounting to a one-week price increase of more than 123.11%. The company report on November 23, 2021 that Pasithea Therapeutics Adds Esketamine Nasal Spray to its Clinic Offerings in the U.K.
Pasithea Clinics is one of only three accredited clinics in the U.K. approved to offer esketamine nasal spray (SPRAVATO®) for treatment of mental health disorders.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, announced that its wholly owned subsidiary, Pasithea Clinics, has been approved to provide esketamine nasal spray (SPRAVATO®) for treatment-resistant depression in adults, and has begun offering the treatment in its Knightsbridge, London location. Only three clinics in the U.K. have been accredited to offer this treatment.
The market cap for the stock reached $73.98 million, with 13.21 million shares outstanding and 5.42 million shares in the current float. Compared to the average trading volume of 512.54K shares, KTTA stock reached a trading volume of 188735261 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Pasithea Therapeutics Corp. [KTTA]:
The Average True Range (ATR) for Pasithea Therapeutics Corp. is set at 0.69 The Price to Book ratio for the last quarter was 98.25, with the Price to Cash per share for the same quarter was set at 1.56.
KTTA Stock Performance Analysis:
Pasithea Therapeutics Corp. [KTTA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 123.11.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for KTTA stock in for the last two-week period is set at 82.00, with the RSI for the last a single of trading hit 87.33, and the three-weeks RSI is set at 76.35 for Pasithea Therapeutics Corp. [KTTA], while it was recorded at 2.99 for the last single week of trading.
Insight into Pasithea Therapeutics Corp. Fundamentals:
Pasithea Therapeutics Corp.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 39.80 and a Current Ratio set at 39.80.
Pasithea Therapeutics Corp. [KTTA] Insider Position Details
There are presently around $2 million, or 9.00% of KTTA stock, in the hands of institutional investors. The top three institutional holders of KTTA stocks are: KEPOS CAPITAL LP with ownership of 400,000, which is approximately New of the company’s market cap and around 11.50% of the total institutional ownership; TWO SIGMA SECURITIES, LLC, holding 10,440 shares of the stock with an approximate value of $58000.0 in KTTA stocks shares; and UBS GROUP AG, currently with $18000.0 in KTTA stock with ownership of nearly New of the company’s market capitalization.
4 institutional holders increased their position in Pasithea Therapeutics Corp. [NASDAQ:KTTA] by around 415,564 shares. Additionally, 0 investors decreased positions by around 0 shares, while 0 investors held positions by with 0 shares. The mentioned changes placed institutional holdings at 415,564 shares, according to the latest SEC report filing. KTTA stock had 4 new institutional investments in for a total of 415,564 shares, while 0 institutional investors sold positions of 0 shares during the same period.